Technology transfer

A core part of the ICB strategy is the promotion of innovation achieved through both the utilization of the intellectual property of ICB researchers and the technology transfer facilitation. Technology transfer activities of ICB for the period 2018 -2025 include:

• Licensing (assignment) of the patent application “Bio-inspired proteasome activators with anti-ageing activity” (Inventors: Koufaki M., Calogeropoulou T., Chondrogianni N., Papahatjis D., Gonos E.S., Fotopoulou T., Proussis K., Chazapi E.) to the company InterMed SA to develop new cosmetic formulations. NHRF will receive royalties from the product’s annual sales.
• Licensing (assignment) of the patent application “Compound for use in the treatment of protozoal diseases and process for production of said compound” (Inventors: Calogeropoulou T., Prousis, K.C., Roussaki, M., Magoulas, G.E., Fotopoulou T.) to the company Quadrel Srl. to develop anti-parasitic drug for veterinary applications.
• Licensing of the patent application “Macrocyclic rescuers for disease-associated protein misfolding” (Inventors: Skretas, G.) to the company ResQ Biotech to develop potentially therapeutic agents against diseases caused by protein misfolding and aggregation. NHRF has received equity in the company.
• Acquisition on 10/2022 of the start-up company Quadrel Srl (co-founded in 2020 by T. Calogeropoulou) by the multinational veterinary pharmaceutical industry Fatro SpA to develop a drug against canine leishmaniasis. NHRF received income from the sale.
• NerveRepack: advanced materials and next-generation bidirectional implanted electrodes that link the human Central Nervous System to external mechanical assistive devices (e.g., exoskeletons and exoprostheses). Presented at the 88th and 89th Thessaloniki International Fair (TIF); marketing, translation, and diffusion. (T. Katsila)
• CLOUDSCREEN^®: one-stop-shop drug-repurposing platform; marketing, translation, and diffusion. Collaboration with CLOUDPHARM PC and COSMOS HEALTH INC for the commercial exploitation of CLOUDSCREEN^® (T. Katsila)
• NanoSpot.ai™: rapid SARS-CoV-2 antibody diagnostic test. Presented at the 86th Thessaloniki International Fair (TIF); marketing, translation, and diffusion (T. Katsila)
• Photostick™: pre-clinical pre-validation of a point-of-care photosensor; marketing, translation, and diffusion Collaboration with ATHROA Innovation PC and OPTO Immunosensors PC for the development and utilization of NanoSpot.ai™ (T. Katsila)
• IN3^© : one-stop-shop “innovation engine” IN3 is a tri-modal innovation engine that fuses in silico, in vitro, and in vivo approaches into a single framework, designed to fast-track safe, effective advanced materials, smart systems, and therapeutics from concept to society (T. Katsila)
• Collaboration with the company CLEANWAY: Pilot-scale production of a line of cosmetics for sun protection (TANGO FACE & BODY SUN LOTION SPF 30 and SPF 50) based on the technology of nanoencapsulation of bioactive ingredients found in olive oil and/or olive mill waste or spirulina, which have the potential to enhance antioxidant and sun protection. ( Papadimitriou)
• Collaboration with the company Theracell: Pilot-scale production of a cosmetic moisturizing body lotion based on nanoemulsion technology of plant oils with moisturizing and insect-repellent properties. (V. Papadimitriou)
  Inventors: ZOGRAFOS, Spyridon, TSITSANOU Aikaterini, LINGRI Panagiota, STAMATI Evgenia, ZOUMPOULAKIS Panagiotis, TSIAKA Thaleia, PAPADIMITRIOU Vasiliki, CHATZIDAKI Maria, DEMISLI Sotiria, MICHAILAKIS Antonios, PAPACHRISTOS Dimitrios, SOTIROPOULOU Georgia, ZINGKOU Eleni